Volunteer Assignments and Opportunities: Difference between revisions
No edit summary |
Snehal.Patel (talk | contribs) No edit summary |
||
| (170 intermediate revisions by 10 users not shown) | |||
| Line 1: | Line 1: | ||
{| class="wikitable" | {| class="wikitable" | ||
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content | |||
|- | |- | ||
!'''Disease'''!!'''Page Type'''!!'''Author''' | !'''Disease'''!!'''Page Type'''!!'''Author''' | ||
| Line 25: | Line 17: | ||
| | | | ||
|Fabiola Quintero-Rivera (FQR) | |Fabiola Quintero-Rivera (FQR) | ||
| | | | ||
| | | | ||
|- | |- | ||
| Line 35: | Line 27: | ||
| | | | ||
|FQR | |FQR | ||
| | | | ||
| | | | ||
|- | |- | ||
| Line 45: | Line 37: | ||
| | | | ||
|FQR | |FQR | ||
| | | | ||
| | | | ||
|- | |- | ||
| Line 69: | Line 61: | ||
|- | |- | ||
| Essential Thrombocythaemia (ET)||Disease | | Essential Thrombocythaemia (ET)||Disease | ||
|Rebecca Smith | |Rebecca Smith (trainee) + Fabiola Quintero-Rivera | ||
| | | | ||
| | | | ||
|complete | |complete/pending faculty review | ||
| | | | ||
|FQR | |FQR | ||
| Line 79: | Line 71: | ||
|- | |- | ||
| Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease | | Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease | ||
| | |(trainee), Daynna J.Wolff | ||
| | | | ||
| | | | ||
| | |pending faculty review | ||
| | | | ||
|FQR | |FQR | ||
| Line 90: | Line 82: | ||
| Myeloproliferative Neoplasm (MPN), Unclassifiable||Disease | | Myeloproliferative Neoplasm (MPN), Unclassifiable||Disease | ||
|Thomas Lee | |Thomas Lee | ||
| | |8/17/2020 | ||
| | |9/7/2020 | ||
|complete | |complete | ||
| | | | ||
| Line 98: | Line 90: | ||
| | | | ||
|- | |- | ||
|'''''Mastocytosis'''''||'''''Overview'''''||Shashi Shetty, Ph.D. | |'''''Mastocytosis'''''||'''''Overview'''''||'''Shashi Shetty, Ph.D.''' | ||
| | | | ||
| | | | ||
| Line 107: | Line 99: | ||
|- | |- | ||
| Cutaneous Mastocytosis||Disease | | Cutaneous Mastocytosis||Disease | ||
|Thuy Phung | |Thuy Phung/Shuo-Shawn Liu | ||
| | | | ||
| | | | ||
|complete | |complete/pending adding content online as of 2/4/21 | ||
| | | | ||
|FQR | |FQR | ||
| Line 127: | Line 119: | ||
|- | |- | ||
| Mast Cell Sarcoma||Disease | | Mast Cell Sarcoma||Disease | ||
|Thuy Phung +Jordan Lowery | |Thuy Phung +Jordan Lowery | ||
| | | | ||
| | | | ||
| Line 183: | Line 175: | ||
|Myeloid/Lymphoid Neoplasms with ETV6-JAK2 | |Myeloid/Lymphoid Neoplasms with ETV6-JAK2 | ||
|Disease | |Disease | ||
|Lauren R. Crowson | |Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff | ||
| | | | ||
| | | | ||
| Line 194: | Line 186: | ||
|Myeloid/Lymphoid Neoplasms with BCR-JAK2 | |Myeloid/Lymphoid Neoplasms with BCR-JAK2 | ||
|Disease | |Disease | ||
|Lauren R. Crowson | |Lauren R. Crowson (trainee) + Daynna J. Wolff | ||
| | | | ||
| | | | ||
| Line 233: | Line 225: | ||
| | | | ||
|9/1/20 | |9/1/20 | ||
|PENDING | |PENDING | ||
| | | | ||
|FQR | |FQR | ||
| | | | ||
| | | | ||
|- | |- | ||
| Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera | | Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera | ||
| Line 245: | Line 237: | ||
| | | | ||
|FQR | |FQR | ||
| | | | ||
| | | | ||
|- | |- | ||
| Line 257: | Line 249: | ||
| | | | ||
|- | |- | ||
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''|| | |'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek? | ||
| | | | ||
| | |9/1/20 | ||
|pending | |pending | ||
| | | | ||
| Line 295: | Line 287: | ||
| Myelodysplastic Syndrome (MDS) with Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek | | Myelodysplastic Syndrome (MDS) with Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek | ||
| | | | ||
| | |9/1/20 | ||
| | |PENDING | ||
| | | | ||
|FQR | |FQR | ||
| Line 305: | Line 297: | ||
| | | | ||
|9/1/20 | |9/1/20 | ||
| | |PENDING | ||
| | | | ||
|FQR | |FQR | ||
| Line 332: | Line 324: | ||
| | | | ||
|9/1/20 | |9/1/20 | ||
| | |PENDING | ||
| | | | ||
|FQR | |FQR | ||
| Line 338: | Line 330: | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | | | ||
| | | | ||
| | |||
| || | |||
| | | | ||
| | | | ||
|- | |- | ||
|'''''Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms'''''||'''''Overview'''''||Daynna Wolff+Daniel Butler (Path Resident) | |'''''Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms'''''||'''''Overview'''''||Daynna Wolff+Daniel Butler (Path Resident) | ||
| Line 368: | Line 358: | ||
| | | | ||
| | | | ||
| | |PENDING | ||
| ||JH / MS | | ||JH / MS | ||
|04/26/2021 -MS (re-review) | |04/26/2021 -MS (re-review) | ||
| | | | ||
|- | |- | ||
| Myeloid Neoplasms with Germline DDX41 Mutation||Disease||Fei Yang | | Myeloid Neoplasms with Germline DDX41 Mutation||Disease||Fei Yang | ||
| Line 478: | Line 468: | ||
| | | | ||
|- | |- | ||
| Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease||Kay Weng Choy + Greg | | Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease||Kay Weng Choy + Greg Conboy (Monash Health) | ||
| | | | ||
| | | | ||
| Line 487: | Line 476: | ||
| | | | ||
|- | |- | ||
| Acute Myeloid Leukemia (AML) with Mutated NPM1||Disease||Xinjie Xu | | Acute Myeloid Leukemia (AML) with Mutated NPM1||Disease||Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health) | ||
| | | | ||
| | | | ||
| Line 495: | Line 484: | ||
|Add WHO reference | |Add WHO reference | ||
|- | |- | ||
| Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg | | Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg Conboy (Monash Health) | ||
| | | | ||
| | | | ||
| Line 713: | Line 702: | ||
|Acute Myeloid Leukemia (AML) with Mutated FLT3 | |Acute Myeloid Leukemia (AML) with Mutated FLT3 | ||
|Disease | |Disease | ||
|Kay Weng Choy + Greg | |Kay Weng Choy + Greg Conboy (Monash Health) | ||
| | | | ||
| | | | ||
| Line 756: | Line 745: | ||
| | | | ||
| | | | ||
| || | | ||Yassmine Akkari (YA) | ||
| | |||
| | | | ||
|- | |- | ||
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''|| | |'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''|| | ||
| Line 764: | Line 753: | ||
| | | | ||
| | | | ||
| || | | ||YA | ||
| | |||
| | | | ||
|- | |- | ||
| B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease||Afia Hasnain | | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease||Afia Hasnain + Yassmine Akkari | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| || | | ||YA | ||
| | |||
| | | | ||
|- | |- | ||
| B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee) | | B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee) | ||
| Line 781: | Line 770: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |YA | ||
| | |||
| | | | ||
|- | |- | ||
| B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||Marilena Melas + Yassmine Akkari | | B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||Marilena Melas + Yassmine Akkari | ||
| Line 789: | Line 778: | ||
| | | | ||
|PENDING | |PENDING | ||
| || | | ||YA | ||
| | |||
| | | | ||
|- | |- | ||
| B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease||Afia Hasnain + Yassmine Akkari | | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease||Afia Hasnain + Yassmine Akkari | ||
| Line 797: | Line 786: | ||
| | | | ||
|PENDING | |PENDING | ||
| || | | ||YA | ||
| | |||
| | | | ||
|- | |- | ||
| B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy||Disease||Ashwini Yenamandra + | | B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy||Disease||Ashwini Yenamandra + | ||
| Line 808: | Line 797: | ||
|Complete | |Complete | ||
| | | | ||
| | |YA | ||
| | |||
| | | | ||
|- | |- | ||
| B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease||Binu Porath + Linda Cooley | | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease||Binu Porath + Linda Cooley | ||
| Line 816: | Line 805: | ||
| | | | ||
|PENDING | |PENDING | ||
| || | | ||YA | ||
| | |||
| | | | ||
|- | |- | ||
| B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease||Binu Porath + Linda Cooley | | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease||Binu Porath + Linda Cooley | ||
| Line 824: | Line 813: | ||
| | | | ||
|PENDING | |PENDING | ||
| || | | ||YA | ||
| | |||
| | | | ||
|- | |- | ||
| B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera | | B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera | ||
| Line 833: | Line 822: | ||
|Complete | |Complete | ||
| | | | ||
| | |YA | ||
| | |||
| | | | ||
|- | |- | ||
| B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease||Holli Drendel | | B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease||Holli Drendel | ||
| | | | ||
| | | | ||
| | |PENDING | ||
| || | | ||YA | ||
| | |||
| | | | ||
|- | |- | ||
| B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease||Holli Drendel | | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease||Holli Drendel | ||
| Line 849: | Line 838: | ||
| | | | ||
|PENDING | |PENDING | ||
| || | | ||YA | ||
| | |||
| | | | ||
|- | |- | ||
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 | |B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 | ||
| Line 860: | Line 849: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |YA | ||
| | | | ||
| | |NON-WHO ENTITY | ||
|- | |- | ||
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 | |B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 | ||
| Line 871: | Line 860: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |YA | ||
| | | | ||
| | |NON-WHO ENTITY | ||
|- | |- | ||
|B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements | |B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements | ||
| Line 882: | Line 871: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |YA | ||
| | | | ||
| | |NON-WHO ENTITY | ||
|- | |- | ||
|B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions | |B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions | ||
| Line 893: | Line 882: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |YA | ||
| | | | ||
| | |NON-WHO ENTITY | ||
|- | |- | ||
|B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) | |B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) | ||
| Line 904: | Line 893: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |YA | ||
| | | | ||
| | |NON-WHO ENTITY | ||
|- | |- | ||
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) | |B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) | ||
| Line 915: | Line 904: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |YA | ||
| | | | ||
| | |NON-WHO ENTITY | ||
|- | |- | ||
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||Fei Yang | |'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||Fei Yang | ||
| Line 923: | Line 912: | ||
| | | | ||
|PENDING | |PENDING | ||
| || | | ||YA | ||
| | |||
| | | | ||
|- | |- | ||
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||Fei Yang | |Early T-Cell Precursor Lymphoblastic Leukemia||Disease||Fei Yang | ||
| Line 931: | Line 920: | ||
| | | | ||
|PENDING | |PENDING | ||
| || | | ||YA | ||
| | |||
| | | | ||
|- | |- | ||
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang | |NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang | ||
| Line 939: | Line 928: | ||
| | | | ||
|PENDING | |PENDING | ||
| || | | ||YA | ||
| | |||
| | | | ||
|- | |- | ||
| || || | | || || | ||
| Line 955: | Line 944: | ||
| | | | ||
| | | | ||
| || | | ||Snehal Patel (SP) | ||
| | |||
| | | | ||
|- | |- | ||
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease|| | |Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease|| | ||
| | |||
| | |||
| | | | ||
| | | | ||
| | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| Monoclonal B-cell Lymphocytosis||Disease|| | | Monoclonal B-cell Lymphocytosis||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | |||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
|B-cell Prolymphocytic Leukemia||Disease|| | |B-cell Prolymphocytic Leukemia||Disease|| | ||
| Line 984: | Line 971: | ||
| | | | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel | |Splenic Marginal Zone Lymphoma||Disease||Snehal Patel | ||
| Line 993: | Line 980: | ||
|Complete | |Complete | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
|Hairy Cell Leukemia||Disease||Snehal Patel | |Hairy Cell Leukemia||Disease||Snehal Patel | ||
| Line 1,002: | Line 989: | ||
|Complete | |Complete | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel | |'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel | ||
| Line 1,011: | Line 998: | ||
|Complete | |Complete | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
| Splenic Diffuse Red Pulp Small B-cell Lymphoma||Disease||Snehal Patel | | Splenic Diffuse Red Pulp Small B-cell Lymphoma||Disease||Snehal Patel | ||
| Line 1,020: | Line 1,007: | ||
|Complete | |Complete | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
| Hairy Cell Leukemia Variant||Disease||Snehal Patel | | Hairy Cell Leukemia Variant||Disease||Snehal Patel | ||
| Line 1,029: | Line 1,016: | ||
|Complete | |Complete | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
|Lymphoplasmacytic Lymphoma||Disease|| | |Lymphoplasmacytic Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |SP | ||
| | | | ||
| | |||
|- | |- | ||
| Waldenstrom Macroglobulinemia||Disease|| | | Waldenstrom Macroglobulinemia||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |SP | ||
| | | | ||
| | |||
|- | |- | ||
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| | |IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| | ||
| Line 1,055: | Line 1,042: | ||
| | | | ||
| | | | ||
| || | | ||SP | ||
| | |||
| | | | ||
|- | |- | ||
|'''''Heavy Chain Diseases'''''||'''''Overview'''''|| | |'''''Heavy Chain Diseases'''''||'''''Overview'''''|| | ||
| Line 1,063: | Line 1,050: | ||
| | | | ||
| | | | ||
| || | | ||SP | ||
| | |||
| | | | ||
|- | |- | ||
| Mu Heavy Chain Disease||Disease|| | | Mu Heavy Chain Disease||Disease|| | ||
| Line 1,071: | Line 1,058: | ||
| | | | ||
| | | | ||
| || | | ||SP | ||
| | |||
| | | | ||
|- | |- | ||
| Gamma Heavy Chain Disease||Disease||Manisha Sutariya | | Gamma Heavy Chain Disease||Disease||Manisha Sutariya | ||
| Line 1,079: | Line 1,066: | ||
| | | | ||
|Complete | |Complete | ||
|5/26/2021|| | |5/26/2021||SP | ||
| | |||
| | | | ||
|- | |- | ||
| Alpha Heavy Chain Disease||Disease|| | | Alpha Heavy Chain Disease||Disease|| | ||
| Line 1,087: | Line 1,074: | ||
| | | | ||
| | | | ||
| || | | ||SP | ||
| | |||
| | | | ||
|- | |- | ||
|Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang | |Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang | ||
| Line 1,096: | Line 1,083: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
| Non-IgM Monoclonal Gammopathy of Undetermined Significance||Disease||Zhenya Tang | | Non-IgM Monoclonal Gammopathy of Undetermined Significance||Disease||Zhenya Tang | ||
| Line 1,105: | Line 1,092: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
| Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee) | | Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee) | ||
| Line 1,114: | Line 1,101: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
| Plasma Cell Myeloma Variants||Disease||Fariborz Rashid-Kolvear | | Plasma Cell Myeloma Variants||Disease||Fariborz Rashid-Kolvear | ||
| Line 1,123: | Line 1,110: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
| Plasmacytoma||Disease||Zhenya Tang | | Plasmacytoma||Disease||Zhenya Tang | ||
| Line 1,132: | Line 1,119: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
|''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| | |''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| | ||
| | | | ||
| | | | ||
| | | | ||
|SP | | ||SP | ||
| | |||
| | |||
|- | |- | ||
| Primary Amyloidosis||Disease|| | | Primary Amyloidosis||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
|SP | | ||SP | ||
| | |||
| | |||
|- | |- | ||
| Light Chain and Heavy Chain Deposition Disease||Disease|| | | Light Chain and Heavy Chain Deposition Disease||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | ||SP | ||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | POEMS Syndrome||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||SP | ||
| | | | ||
|SP | | | ||
|- | |||
| TEMPI Syndrome||Disease|| | |||
| | |||
| | |||
| | |||
| ||SP | |||
| | |||
| | |||
|- | |||
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee, trainee)/Fabiola Quintero-Rivera | |||
|3/9/21 | |||
| | |||
|PENDING | |||
| | |||
|SP | |||
| | |||
| | |||
|- | |- | ||
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem | |Nodal Marginal Zone Lymphoma||Disease||Shivani Golem | ||
| Line 1,197: | Line 1,184: | ||
| | | | ||
|Complete | |Complete | ||
|5/28/2021|| | |5/28/2021||SP | ||
| | |||
| | | | ||
|- | |- | ||
| Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee) | | Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee) | ||
| | | | ||
| | | | ||
|Complete | |Complete | ||
|11/11/2020 | |11/11/2020 | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
|Follicular Lymphoma||Disease||Ruthann Pfau | |Follicular Lymphoma||Disease||Ruthann Pfau | ||
| Line 1,215: | Line 1,202: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
| Testicular Follicular Lymphoma||Disease||Ruthann Pfau | | Testicular Follicular Lymphoma||Disease||Ruthann Pfau | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
| In Situ Follicular Neoplasia||Disease||Ruthann Pfau | | In Situ Follicular Neoplasia||Disease||Ruthann Pfau | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
| Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau | | Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
|Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee) | |Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee) | ||
| Line 1,251: | Line 1,238: | ||
|Complete | |Complete | ||
|8/16/2020 | |8/16/2020 | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||Afia Hasnaid | |Large B-cell Lymphoma with IRF4 Rearrangement||Disease||Afia Hasnaid | ||
| Line 1,259: | Line 1,246: | ||
|9/30/20 | |9/30/20 | ||
|Complete | |Complete | ||
|5/26/2021|| | |5/26/2021||SP | ||
| | |||
| | | | ||
|- | |- | ||
|Primary Cutaneous Follicle Centre Lymphoma||Disease||Shivani Golem | |Primary Cutaneous Follicle Centre Lymphoma||Disease||Shivani Golem | ||
| | | | ||
| | | | ||
| | |PENDING | ||
| | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
|Mantle Cell Lymphoma||Disease||Mahsa Khanlari | |Mantle Cell Lymphoma||Disease||Mahsa Khanlari | ||
| Line 1,277: | Line 1,263: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |SP | ||
| | |||
| | | | ||
|- | |- | ||
| Leukemic Non-Nodal Mantle Cell Lymphoma||Disease|| | | Leukemic Non-Nodal Mantle Cell Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|SP | |SP | ||
| | |||
| | |||
|- | |- | ||
| || || | | In Situ Mantle Cell Neoplasia||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|SP | |||
| | | | ||
|- | | | ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease||Ashwini Yenamandra | |- | ||
| || || | |||
| | |||
| | |||
| | |||
| || | |||
| | |||
| | |||
|- | |||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease||Ashwini Yenamandra | |||
| | | | ||
| | | | ||
| Line 1,314: | Line 1,300: | ||
|Greg Corboy (GC) | |Greg Corboy (GC) | ||
| | | | ||
| | | | ||
|- | |- | ||
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| | |T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| | ||
| Line 1,324: | Line 1,310: | ||
| | | | ||
|- | |- | ||
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease|| | |Primary Diffuse Large B-cell Lymphoma of the CNS||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease|| | |Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease|| | ||
| Line 1,388: | Line 1,374: | ||
| | | | ||
|- | |- | ||
|Intravascular Large B-cell Lymphoma||Disease|| | |Intravascular Large B-cell Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
|ALK-Positive Large B-cell Lymphoma||Disease|| | |ALK-Positive Large B-cell Lymphoma||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| ||GC | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera | |Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera | ||
| Line 1,409: | Line 1,395: | ||
|Complete | |Complete | ||
| ||GC | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| Line 1,428: | Line 1,414: | ||
| | | | ||
|- | |- | ||
| Multicentric Castleman Disease||Disease|| | | Multicentric Castleman Disease||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| ||GC | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| HHV8-Positive | | HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| ||GC | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | HHV8-Positive Germinotropic Lymphoproliferative Disorder||Disease|| | ||
| | | | ||
| | | | ||
| Line 1,477: | Line 1,438: | ||
| | | | ||
|- | |- | ||
| | |Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy | ||
| | |3/11/21 | ||
| | | | ||
| | |PENDING | ||
| | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Burkitt-Like Lymphoma with 11q Aberration||Disease|| | ||
| | | | ||
| | | | ||
| Line 1,502: | Line 1,454: | ||
| | | | ||
|- | |- | ||
| || || | |'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| ||GC | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||GC | ||
| | |||
| | |||
|- | |- | ||
| | |B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||GC | ||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | | | ||
| | | | ||
| | | | ||
| | | || | ||
| | | | ||
| | | | ||
|- | |||
|'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''|| | |||
| | | | ||
| | | | ||
| | | | ||
| ||Snehal Patel (SP) | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |T-cell Prolymphocytic Leukemia||Disease||Michelle Don | ||
| | | | ||
| | | | ||
|PENDING | |||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don | ||
| | | | ||
| | | | ||
|PENDING | |||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don | ||
| | | | ||
| | | | ||
|PENDING | |||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Aggressive NK-cell Leukemia||Disease|| | ||
| | |||
| | |||
| | | | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''|| | ||
| | |||
| | | | ||
| | | | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee) | ||
| | | | ||
| | | | ||
| | |PENDING | ||
| | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||SP | ||
| | |||
| | |||
| | | | ||
| | | | ||
| | |- | ||
| Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| | |||
| | | | ||
| | | | ||
| | | | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Severe Mosquito Bite Allergy||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Adult T-cell Leukemia/Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||SP | ||
| | | | ||
| | | | ||
|- | |||
|Extranodal NK/T-cell Lymphoma, Nasal Type||Disease|| | |||
| | | | ||
| | | | ||
| | | | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |'''''Intestinal T-cell Lymphoma'''''||'''''Overview'''''||Sumire Kitahara, Derick Okwan (trainee) | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Enteropathy-Associated T-cell Lymphoma||Disease||Sumire Kitahara, Derick Okwan (trainee) | ||
| | | | ||
| | | | ||
| | |Complete | ||
| || | |1/21/2021 | ||
|SP | |||
| | |||
| | | | ||
|- | |- | ||
| | | Monomorphic Epitheliotropic Intestinal T-cell Lymphoma||Disease||Sumire Kitahara | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Sumire Kitahara, Derick Okwan (trainee) | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract||Disease||Sumire Kitahara, Derick Okwan (trainee) | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Hepatosplenic T-cell Lymphoma||Disease||Michelle Don | ||
| | | | ||
| | | | ||
|Complete | |||
|1/21/2021 | |||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Mycosis Fungoides||Disease||Daynna Wolff, Jane Scribner (trainee) | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee) | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''|| | ||
| | |||
| | |||
| | | | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Lymphomatoid Papulosis||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| || || | |'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||SP | ||
| | | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
|'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''|| | |||
|''''' | |||
| | | | ||
| | | | ||
| | | | ||
| || | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Angioimmunoblastic T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee) | ||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
| | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Follicular T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee) | ||
| | |||
| | | | ||
|PENDING | |||
| | |||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease||Hans Hamnvåg | ||
| | | | ||
| | | | ||
| | |PENDING | ||
| || | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara | ||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
| | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara | ||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
| | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||Sumire Kitahara | ||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
| | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | | | ||
| | | | ||
| | | | ||
| || | | || | ||
| | | | ||
| | | | ||
|- | |- | ||
|''''' | |'''''Hodgkin Lymphomas'''''||'''''Overview'''''|| | ||
| | | | ||
| | | | ||
| | | | ||
| ||GC | | ||Greg Corboy (GC) | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease|| | ||
| | |||
| | |||
| | |||
| ||GC | |||
| | | | ||
| | | | ||
|- | |- | ||
|''''' | |'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''|| | ||
| | | | ||
| | | | ||
| Line 1,988: | Line 1,833: | ||
| | | | ||
|- | |- | ||
| | | Nodular Sclerosis Classic Hodgkin Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| Line 2,012: | Line 1,849: | ||
| | | | ||
|- | |- | ||
| | | Mixed Cellularity Classic Hodgkin Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| Line 2,020: | Line 1,857: | ||
| | | | ||
|- | |- | ||
| | | Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease|| | ||
| | | | ||
| | | | ||
| Line 2,028: | Line 1,865: | ||
| | | | ||
|- | |- | ||
| | |'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| | ||
| | | | ||
| | | | ||
| Line 2,036: | Line 1,873: | ||
| | | | ||
|- | |- | ||
| | |Lymphomas Associated with HIV Infection||Disease|| | ||
| | | | ||
| | | | ||
| Line 2,044: | Line 1,881: | ||
| | | | ||
|- | |- | ||
| | |'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''|| | ||
| | | | ||
| | | | ||
| Line 2,052: | Line 1,889: | ||
| | | | ||
|- | |- | ||
| | | Non-Destructive Post-Transplant Lymphoproliferative Disorders||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| ||GC | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| || || | | Polymorphic Post-Transplant Lymphoproliferative Disorders||Disease||Anna Shestakova (trainee)''+,'' | ||
Fabiola Quintero-Rivera | |||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
| | |GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| || || | |''''' Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| || || | | Monomorphic B-cell PTLD||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| || || | | Monomorphic T/NK-cell PTLD||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| || || | | Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| || || | |Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
|'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''|| | |||
| | |||
| | |||
| | |||
| ||GC | |||
| | |||
| | |||
|- | |- | ||
| | |Histiocytic Sarcoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''|| | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Langerhans Cell Histiocytosis||Disease|| | ||
| | | | ||
| | |||
| | | | ||
| | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Langerhans Cell Sarcoma||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Indeterminate Dendritic Cell Tumour||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||GC | ||
| | | | ||
| | | | ||
|- | |||
|Interdigitating Dendritic Cell Sarcoma||Disease|| | |||
| | | | ||
| | | | ||
| | | | ||
| ||GC | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Follicular Dendritic Cell Sarcoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| ||GC | |||
| | | | ||
| | | | ||
|- | |||
| Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease|| | |||
| | | | ||
| | | | ||
| | | | ||
| ||GC | |||
| | | | ||
| | | | ||
|- | |||
|Fibroblastic Reticular Cell Tumor||Disease|| | |||
| | | | ||
| | | | ||
| | |||
| ||GC | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Disseminated Juvenile Xanthogranuloma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||GC | ||
| | |||
| | | | ||
|- | |- | ||
| | |Erdheim-Chester Disease||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| | | ||GC | ||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | | | ||
| | | | ||
| | | | ||
| | | || | ||
| | | | ||
| | | | ||
|- | |||
| || || | |||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |||
| || || | |||
| | | | ||
| | | | ||
| | | | ||
| | | || | ||
| | | | ||
| | | | ||
|- | |||
| || || | |||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |||
| || || | |||
| | | | ||
| | | | ||
| | | | ||
| | | || | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | | | ||
| | | | ||
| | |||
| || | |||
| | | | ||
| | | | ||
|- | |||
| || || | |||
| | | | ||
| | | | ||
| | | | ||
| | | || | ||
| | | | ||
| | | | ||
|- | |||
| || || | |||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | |||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |||
| || || | |||
| | | | ||
| | | | ||
| | | | ||
| | | || | ||
| | | | ||
| | | | ||
|- | |||
| || || | |||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | | | ||
| | | | ||
| | | | ||
| || | |||
| | | | ||
| | | | ||
|} | |} | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|+Gene-Specific Pages | |||
!'''Gene''' | !'''Gene''' | ||
!'''Author''' | !'''Author''' | ||